Roche Advances Hemophilia Gene Therapy in Phase III, Terminates Another

Roche has announced the removal of RG6358, or SPK-8016, from its gene therapy pipeline for hemophilia A, while initiating a Phase III trial for RG6357, or SPK-8011. The company plans to open enrollment for the study, named Keystone1, later this year.